Arrowhead Soars 25% on Major Sarepta Licensing Collaboration
Arrowhead Pharmaceuticals' shares surged after announcing a $11.38 billion licensing deal with Sarepta Therapeutics for gene-silencing products. The agreement includes $825 million upfront, $250 million over five years, $300 million in near-term milestones, and up to $10 billion in future milestones and royalties. This deal strengthens Sarepta's pipeline in neuromuscular and genetic treatments, while extending Arrowhead's cash runway into 2028. Both companies' stocks rose significantly following the announcement.
